J David Ii Boyle Net Worth

The estimated Net Worth of J David Ii Boyle is at least 136 千$ dollars as of 17 August 2005. J Boyle owns over 5,000 units of XOMA Royalty stock worth over 135,600$ and over the last 19 years J sold XOMA stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

J Boyle XOMA stock SEC Form 4 insiders trading

J has made over 1 trades of the XOMA Royalty stock since 2005, according to the Form 4 filled with the SEC. Most recently J bought 5,000 units of XOMA stock worth 7,200$ on 17 August 2005.

The largest trade J's ever made was buying 5,000 units of XOMA Royalty stock on 17 August 2005 worth over 7,200$. On average, J trades about 625 units every 0 days since 2005. As of 17 August 2005 J still owns at least 5,000 units of XOMA Royalty stock.

You can see the complete history of J Boyle stock trades at the bottom of the page.

What's J Boyle's mailing address?

J's mailing address filed with the SEC is XOMA LTD, 2910 SEVENTH STREET, BERKELEY, CA, 94710.

Insiders trading at XOMA Royalty

Over the last 21 years, insiders at XOMA Royalty have traded over 74,428,857$ worth of XOMA Royalty stock and bought 6,217,869 units worth 44,091,555$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of 3,397,377$. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth 13,830$.

What does XOMA Royalty do?

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.

Complete history of J Boyle stock trades at XOMA Royalty

XOMA Royalty executives and stock owners

XOMA Royalty executives and other stock owners filed with the SEC include:

• James Neal,
  Chief Executive Officer, Director
• Thomas Burns,
  Chief Financial Officer, Senior Vice President - Finance
• James R. Neal,
  CEO & Chairman
• Thomas M. Burns,
  Sr. VP of Fin. & CFO
• Barbara Kosacz,
  Independent Director
• W. Denman Van Ness,
  Independent Chairman of the Board
• Jack Wyszomierski,
  Independent Director
• Joseph Limber,
  Independent Director
• Matthew Perry,
  Independent Director
• Natasha Hernday,
  Director
• Deepshikha Datta,
  Chief Business Officer
• Timothy P Walbert,
  Director
• Peter Barton Hutt,
  Director
• Paul D Rubin,
  VP Clinical Dev. & CMO
• Steven B Engle,
  CEO and President
• Charles J Jr Fisher,
  Director
• Patrick J Zenner,
  Director
• John Varian,
  Director
• Owen Hughes,
  Chief Executive Officer
• Partners L P/Ilbiotechnolog...,
  
• Fred Kurland,
  VP Finance
• Thomas Klein,
  Chief Commercial Officer
• William K Jr Bowes,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lpbaker Feli...,
  
• Bros Advisors Llcbaker Feli...,
  
• Patrick J Md Phd Scannon,
  CSMO
• Kelvin Neu,
  Director
• Julianbaker Bros Advisors L...,
  
• J David Ii Boyle,
  VP, Finance, and CFO
• Arthur Md Kornberg,
  Director
• John L Castello,
  Chairman, CEO & President
• James G Andress,
  Director
• Peter B Davis,
  VP, Finance & CFO
• Clarence L Dellio,
  Sr VP, Operations and COO
• Steven C Mendell,
  Director
• Christopher J Margolin,
  VP, General Counsel & Sec'y
• Partners L P/Ilbiotechnolog...,
  
• Heather L Franklin,
  
• Bradley Sitko,
  Chief Investment Officer